ID: h-c7350d53bb
Hypothesis
Gut-derived butyrate reprograms microglia for amyloid clearance via HDAC2 inhibition
Specific butyrate-producing gut bacteria (e.g., Faecalibacterium, Roseburia) generate systemic butyrate that crosses the blood-brain barrier and inhibits hippocampal microglial HDAC2, leading to hyperacetylation of transcription factors .
neurodegeneration
EvidencePending (0%)📖 5 cit🗣 1 debates✓ 5 support✗ 1 oppose
✓ All Quality Gates Passed
🧪 Overview
Specific butyrate-producing gut bacteria (e.g., Faecalibacterium, Roseburia) generate systemic butyrate that crosses the blood-brain barrier and inhibits hippocampal microglial HDAC2, leading to hyperacetylation of transcription factors that upregulate TREM2-independent phagocytic pathways. This enhances microglial amyloid-beta uptake and lysosomal degradation while suppressing NLRP3 inflammasome activation. Testable prediction: Germ-free AD mice colonized with butyrate-producing bacteria or treated with sodium butyrate will show reduced amyloid plaque burden, increased microglial amyloid phagocytosis rates ex vivo, and decreased IL-1β and caspase-1 levels, compared to controls.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["Gut Butyrate Deficiency<br/>HDAC2 Dysregulation"]
B["Microglial Amyloid<br/>Clearance Impairment"]
C["HDAC2 Inhibition<br/>Microglial Reprogramming"]
D["Butyrate Restoration<br/>Epigenetic Reset"]
E["HDAC2-Butyrate Axis<br/>as AD Prevention Target"]
F["Microglial<br/> epigenetic Therapy"]
A --> B
B --> C
C --> D
D --> E
E --> F
style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style F fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7⚖️ Evidence
⚖️ Evidence Matrix5 supports1 contradicts
Supports
TREM2 drives microglia response to amyloid-β via SYK-dependent and -independent pathways.
Supports
Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer's disease.
Supports
TREM2 Maintains Microglial Metabolic Fitness in Alzheimer's Disease.
Supports
The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases.
Contradicts
CNS effects of sodium butyrate require supraphysiological doses administered systemically (≥300 mg/kg in rodents) that gut-derived butyrate cannot achieve in CSF; colonocyte beta-oxidation and hepatic first-pass metabolism rapidly catabolize portal butyrate, leaving negligible concentrations to cross the BBB
PMID:33785315strong
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — HDAC2
No curated PDB or AlphaFold mapping for HDAC2 yet. Search RCSB →
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for HDAC2 from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for HDAC2.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▼ 0.4%
Volatility
Medium
0.0459
Events (7d)
2
Price History
▼4.9%💾 Resource Usage
LLM Tokens
16,120
$0.0967
Total Cost
$0.0967
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF 5xFAD germ-free mice receive daily intraperitoneal sodium butyrate (300 mg/kg) for 8 weeks starting at 4 months of age, THEN hippocampal amyloid plaque burden will decrease by ≥30% compared to vehi | ≥30% reduction in hippocampal amyloid plaque burden after 8 weeks of sodium butyrate treatment, with increased co-localization of IBA1+ microglia with thioflavi | — no observation — | pending | 0.65 |
| IF germ-free APP/PS1 mice are colonized with human-derived Faecalibacterium prausnitzii (butyrate-producer) vs. Escherichia coli (non-butyrate-producer) via oral gavage for 6 weeks, THEN microglial HD | ≥40% reduction in microglial HDAC2 activity (nuclear extraction + fluorometric assay) and ≥60% increase in Aβ42 uptake by cultured hippocampal microglia isolate | — no observation — | pending | 0.55 |
🔮 Falsifiable Predictions (2)
pendingconf 65%
IF 5xFAD germ-free mice receive daily intraperitoneal sodium butyrate (300 mg/kg) for 8 weeks starting at 4 months of age, THEN hippocampal amyloid plaque burden will decrease by ≥30% compared to vehicle-treated 5xFAD germ-free controls, as measured by thioflavin-S stereology.
Predicted outcome: ≥30% reduction in hippocampal amyloid plaque burden after 8 weeks of sodium butyrate treatment, with increased co-localization of IBA1+ microglia with
Falsification: No significant difference (p>0.05) in hippocampal amyloid plaque burden between sodium butyrate-treated and vehicle-treated groups, or plaque burden increases in the treatment group.
pendingconf 55%
IF germ-free APP/PS1 mice are colonized with human-derived Faecalibacterium prausnitzii (butyrate-producer) vs. Escherichia coli (non-butyrate-producer) via oral gavage for 6 weeks, THEN microglial HDAC2 activity will decrease by ≥40% and ex vivo amyloid phagocytosis rate will increase by ≥60% in th
Predicted outcome: ≥40% reduction in microglial HDAC2 activity (nuclear extraction + fluorometric assay) and ≥60% increase in Aβ42 uptake by cultured hippocampal microgl
Falsification: No significant difference in microglial HDAC2 activity between colonized groups, or HDAC2 activity increases rather than decreases in the Faecalibacterium group; phagocytosis rates remain equivalent o
▸Metadatasource: v1_phase_c_backfill · origin_type: audit_hypothesis_generator
| source | v1_phase_c_backfill |
| origin_type | audit_hypothesis_generator |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.